Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.

Saved in:
Bibliographic Details
Title: Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Authors: Jahn N; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Jahn E; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Saadati M; Saadati Solutions, Ladenburg, Germany., Bullinger L; Department of Hematology, Oncology and Tumor Immunology, Charité University, Berlin, Germany., Larson RA; Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA., Ottone T; Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.; Santa Lucia Foundation, Neuro-Oncohematology, I.R.C.C.S., Rome, Italy., Amadori S; Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy., Prior TW; Case Western Reserve University, Cleveland, OH, USA., Brandwein JM; Department of Medicine, University of Alberta, Edmonton, AB, Canada., Appelbaum FR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Medeiros BC; Division of Hematology, Stanford Comprehensive Cancer Center, Stanford University, Stanford, CA, USA., Tallman MS; Division of Hematologic Malignancies, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ehninger G; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Ganser A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Pallaud C; Novartis Pharmaceuticals, Basel, Switzerland., Gathmann I; Novartis Pharmaceuticals, Basel, Switzerland., Krzykalla J; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Benner A; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Bloomfield CD; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Thiede C; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany., Stone RM; Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, USA., Döhner H; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany. konstanze.doehner@uniklinik-ulm.de.
Source: Leukemia [Leukemia] 2022 Sep; Vol. 36 (9), pp. 2218-2227. Date of Electronic Publication: 2022 Aug 03.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5551
DOI:10.1038/s41375-022-01650-w